126. Cancer Cell. 2018 May 14;33(5):922-936.e10. doi: 10.1016/j.ccell.2018.04.003.Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that PotentlyInhibits HER3 Signaling via HER2-Guided Ligand Blockade.Geuijen CAW(1), De Nardis C(2), Maussang D(1), Rovers E(1), Gallenne T(1),Hendriks LJA(1), Visser T(1), Nijhuis R(1), Logtenberg T(1), de Kruif J(1), Gros P(2), Throsby M(3).Author information: (1)Merus NV, 3584 Utrecht, the Netherlands.(2)Crystal and Structural Chemistry, Bijvoet Center for Biomolecular Research,Department of Chemistry, Faculty of Science, Utrecht University, 3584 Utrecht,the Netherlands.(3)Merus NV, 3584 Utrecht, the Netherlands. Electronic address:m.throsby@merus.nl.HER2-driven cancers require phosphatidylinositide-3 kinase (PI3K)/Akt signalingthrough HER3 to promote tumor growth and survival. The therapeutic benefit ofHER2-targeting agents, which depend on PI3K/Akt inhibition, can be overcome byhyperactivation of the heregulin (HRG)/HER3 pathway. Here we describe an unbiasedphenotypic combinatorial screening approach to identify a bispecificimmunoglobulin G1 (IgG1) antibody against HER2 and HER3. In tumor modelsresistant to HER2-targeting agents, the bispecific IgG1 potently inhibits theHRG/HER3 pathway and downstream PI3K/Akt signaling via a "dock & block"mechanism. This bispecific IgG1 is a potentially effective therapy for breastcancer and other tumors with hyperactivated HRG/HER3 signaling.Copyright Â© 2018 Elsevier Inc. All rights reserved.DOI: 10.1016/j.ccell.2018.04.003 PMID: 29763625 